Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Sells $104,463.04 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Christopher R. Cline sold 5,192 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $20.12, for a total transaction of $104,463.04. Following the sale, the chief financial officer now directly owns 90,038 shares of the company’s stock, valued at approximately $1,811,564.56. This represents a 5.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Travere Therapeutics Trading Up 4.4 %

Shares of NASDAQ TVTX opened at $21.10 on Wednesday. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. Travere Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $21.56. The firm’s 50-day moving average is $18.69 and its 200-day moving average is $15.47.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Wells Fargo & Company upgraded shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $9.00 to $27.00 in a research note on Monday, October 21st. HC Wainwright upped their target price on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, January 15th. Barclays upped their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Scotiabank increased their price objective on shares of Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald began coverage on shares of Travere Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of TVTX. Creative Planning raised its position in shares of Travere Therapeutics by 4.3% in the 3rd quarter. Creative Planning now owns 23,938 shares of the company’s stock valued at $335,000 after acquiring an additional 995 shares during the period. Rhumbline Advisers raised its position in shares of Travere Therapeutics by 2.2% in the 4th quarter. Rhumbline Advisers now owns 121,248 shares of the company’s stock valued at $2,112,000 after acquiring an additional 2,640 shares during the period. R Squared Ltd acquired a new stake in shares of Travere Therapeutics in the 4th quarter valued at approximately $53,000. CWM LLC raised its position in shares of Travere Therapeutics by 158.5% in the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after acquiring an additional 3,065 shares during the period. Finally, Diversified Trust Co raised its position in shares of Travere Therapeutics by 27.5% in the 4th quarter. Diversified Trust Co now owns 14,701 shares of the company’s stock valued at $256,000 after acquiring an additional 3,169 shares during the period.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.